ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptimmune Therapeutics PLC
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Adaptimmune Therapeutics PLC revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Adaptimmune Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.